评论：应对癌症靶向治疗的挑战。
Commentary: tackling the challenges of developing targeted therapies for cancer.
机构信息
Section of Hematology-Oncology, University of Chicago, Chicago, Illinois 60637, USA.
出版信息
Oncologist. 2010;15(5):484-7. doi: 10.1634/theoncologist.2010-0079.
Abstract
This article comments on the approaches to solving problems in the development of targeted drug therapies for cancer as outlined by expert collaborative panels and described in this issue by Amit et al., Abrams et al., and Clark et al.
摘要
本文对专家协作小组提出的、本文 Amit 等人、Abrams 等人以及 Clark 等人描述的癌症靶向药物治疗发展中问题的解决方法进行了评论。
相似文献
1
Commentary: tackling the challenges of developing targeted therapies for cancer.
Oncologist. 2010;15(5):484-7. doi: 10.1634/theoncologist.2010-0079.
2
[Exploiting functional dependencies in cancer cells for the development of targeted therapies].
Dtsch Med Wochenschr. 2013 Jun;138(25-26):1369-72. doi: 10.1055/s-0033-1343244. Epub 2013 Jun 12.
3
Book explores challenges in developing cancer drugs: British oncologist discusses "random, unpredictable world" of biotechnology.
Cancer. 2013 Oct 15;119(20):3581-2. doi: 10.1002/cncr.28388.
4
Introduction: the rationale for the development of targeted drugs in cancer therapy.
Recent Results Cancer Res. 2007;172:1-3. doi: 10.1007/978-3-540-31209-3_1.
5
Unique issues in the development of "targeted" antineoplastic pharmaceutical agents.
Curr Oncol Rep. 2005 Jul;7(4):235-6. doi: 10.1007/s11912-005-0043-8.
6
Are targeted therapies really targeted?
Clin Adv Hematol Oncol. 2003 Dec;1(12):722-3.
7
Evolution of targeted therapies in cancer: opportunities and challenges in the clinic.
Future Oncol. 2015;11(2):279-93. doi: 10.2217/fon.14.198.
8
Molecular-targeted therapies: lessons from years of clinical development.
Cancer Treat Rev. 2008 Feb;34(1):61-80. doi: 10.1016/j.ctrv.2007.07.019. Epub 2007 Sep 10.
9
The potential successes and challenges of targeted anticancer therapies.
Curr Opin Support Palliat Care. 2010 Mar;4(1):16-8. doi: 10.1097/SPC.0b013e3283357619.
10
Obstacles and opportunities in the clinical development of targeted therapeutics.
Prog Drug Res. 2005;63:19-41. doi: 10.1007/3-7643-7414-4_2.
引用本文的文献
1
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells.
Cancers (Basel). 2024 Jul 7;16(13):2478. doi: 10.3390/cancers16132478.
2
mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [F] fluorodeoxyglucose (F-FDG PET).
Oncotarget. 2018 Feb 16;9(18):14306-14310. doi: 10.18632/oncotarget.24508. eCollection 2018 Mar 6.
3
Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.
Target Oncol. 2017 Aug;12(4):401-412. doi: 10.1007/s11523-017-0500-y.
4
A Patient Focused Solution for Enrolling Clinical Trials in Rare and Selective Cancer Indications: A Landscape of Haystacks and Needles.
Drug Inf J. 2012 Jul;46(4):472-478. doi: 10.1177/0092861512443436.
5
Vitamin D supplementation and breast cancer prevention: a systematic review and meta-analysis of randomized clinical trials.
PLoS One. 2013 Jul 22;8(7):e69269. doi: 10.1371/journal.pone.0069269. Print 2013.
6
Prediction of chemical-protein interactions network with weighted network-based inference method.
PLoS One. 2012;7(7):e41064. doi: 10.1371/journal.pone.0041064. Epub 2012 Jul 16.
7
Molecular profiling for personalized cancer care.
Clin Exp Metastasis. 2012 Oct;29(7):653-5. doi: 10.1007/s10585-012-9483-3. Epub 2012 Jun 8.
本文引用的文献
1
Blinded independent central review of the progression-free survival endpoint.
Oncologist. 2010;15(5):492-5. doi: 10.1634/theoncologist.2009-0261.
2
Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Clin Cancer Res. 2008 May 15;14(10):2895-9. doi: 10.1158/1078-0432.CCR-07-2248.
3
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science. 2007 May 18;316(5827):1039-43. doi: 10.1126/science.1141478. Epub 2007 Apr 26.
4
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Cancer Res. 2006 Feb 1;66(3):1500-8. doi: 10.1158/0008-5472.CAN-05-2925.
5
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
N Engl J Med. 2005 Feb 24;352(8):786-92. doi: 10.1056/NEJMoa044238.
Zotero 插件